- Home
- HBB vs CMPS Comparison
HBB vs CMPS Comparison
Compare HBB & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- CMPS
- Stock Information
- Founded
- HBB 1904
- CMPS 2020
- Country
- HBB United States
- CMPS United Kingdom
- Employees
- HBB N/A
- CMPS N/A
- Industry
- HBB Home Furnishings
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- CMPS Health Care
- Exchange
- HBB Nasdaq
- CMPS Nasdaq
- Market Cap
- HBB 242.8M
- CMPS 364.9M
- IPO Year
- HBB 2017
- CMPS 2020
- Fundamental
- Price
- HBB $17.63
- CMPS $2.82
- Analyst Decision
- HBB
- CMPS Strong Buy
- Analyst Count
- HBB 0
- CMPS 7
- Target Price
- HBB N/A
- CMPS $17.83
- AVG Volume (30 Days)
- HBB 26.2K
- CMPS 4.5M
- Earning Date
- HBB 07-30-2025
- CMPS 07-31-2025
- Dividend Yield
- HBB 2.72%
- CMPS N/A
- EPS Growth
- HBB 18.18
- CMPS N/A
- EPS
- HBB 2.43
- CMPS N/A
- Revenue
- HBB $659,788,000.00
- CMPS N/A
- Revenue This Year
- HBB N/A
- CMPS N/A
- Revenue Next Year
- HBB N/A
- CMPS N/A
- P/E Ratio
- HBB $7.32
- CMPS N/A
- Revenue Growth
- HBB 5.46
- CMPS N/A
- 52 Week Low
- HBB $13.25
- CMPS $2.25
- 52 Week High
- HBB $31.78
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- HBB 48.06
- CMPS 32.62
- Support Level
- HBB $17.32
- CMPS $2.25
- Resistance Level
- HBB $18.49
- CMPS $2.82
- Average True Range (ATR)
- HBB 0.82
- CMPS 0.41
- MACD
- HBB -0.02
- CMPS -0.27
- Stochastic Oscillator
- HBB 40.89
- CMPS 14.14
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.